スプートニクV COVID-19ワクチン
com/world/article-putin-orders-russian-authorities-to-begin-mass-voluntary-covid-1// 2020年12月3日閲覧。
↑ “COVID-19: Moscow opens Sputnik V clinics – but 100,000 have already had it” (英語). Sky News. https://news.sky.com/story/covid-19-moscow-vaccine-launch-is-more-of-a-pr-event-100-000-have-already-had-it-12151854
↑ “Russia to vaccinate two million against COVID-19 in Dec - RDIF head to BBC”. Reuters (2020年12月4日). 2020年9月21日閲覧。
↑ “About 6.9 mln doses of Sputnik V vaccine to enter circulation in Russia by end of February”. TASS (2020年12月10日). 2020年9月21日閲覧。
↑ “Coronavirus in Russia: The Latest News”. The Moscow Times (2020年12月22日). 2020年9月21日閲覧。
↑ “プーチン氏がワクチン接種 政府が発表、種類は明かさず”. 朝日新聞 (2021年3月24日). 2021年4月7日閲覧。
↑ “プーチン大統領が接種を受けたワクチンは? 「スプートニクV」だったと公表”. スプートニク.
com/coronavirus-pandemic/video-uae-volunteers-receive-russian-covid-19-vaccine
↑ “Dr Reddy's gets DCGI nod for Covid-19 vaccine Sputnik V Phase III trials”. The Times Of India. (2021年1月15日). https://timesofindia.indiatimes.com/business/india-business/dr-reddys-gets-dcgi-nod-for-covid-19-vaccine-sputnik-v-phase-iii-trials/articleshow/80291011.cms
↑ 臨床試験番号 NCT04642339 研究名 "Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela" - ClinicalTrials.gov
↑ Logunov, Denis (2021-02-02). “Sputnik V COVID-19 vaccine candidate appears safe and effective”. The Lancet. doi:10.1016/S0140-6736(21)00234-8. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext.
↑ The Guardian: Sputnik V vaccine has 91.
org/news/2020/08/russia-s-approval-covid-19-vaccine-less-meets-press-release 2020年8月13日閲覧。
1 2 “Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia”. The Lancet. (2021-02-02). doi:10.1016/s0140-6736(21)00234-8. PMC 7852454. PMID 33545094. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852454/.
↑ “Глава РФПИ объяснил значение буквы "V" в названии "Спутника V"” (ロシア語). РИА Новости (2020年12月24日). 2021年5月28日閲覧。
1 2 3 4 “Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia”. Lancet 396 (10255): 887–897.